Sidedness Biomarker - Fight Colorectal Cancer

Sidedness Biomarker

Where your tumor starts in the colon or rectum matters. It can affect what symptoms you notice, what recovery after surgery looks like, and, for some people, which treatments work best. Right- and left-sided colorectal cancers are so different biologically that they're almost like two distinct diseases in the same organ. Doctors call a tumor's location its "sidedness," and it is considered a biomarker.

Back to Colorectal Cancer Biomarkers

Table of Contents

Sponsored By

Your colon's two sides

Your colon runs in a loop through your abdomen. It starts on the lower right side and ends on the left at the rectum. Up to 70% of people with colorectal cancer have tumors on the left side. 

Right side: 

  • Cecum (where the small intestine connects to the colon)
  • Ascending colon 
  • Right half of the transverse colon (the section that crosses the top of your abdomen) 

Left side: 

  • Left half of the transverse colon 
  • Descending colon 
  • Sigmoid colon (the S-shaped section where left-sided cancers most often develop) 
  • Rectum (not technically part of the colon, but considered left-sided) 

A note about rectal cancer: Treatment for rectal cancer is different from colon cancer, including when surgery happens. If your rectal cancer is MSI-H/dMMR, immunotherapy may be recommended first. In some cases, it may mean radiation, chemotherapy, or surgery isn’t needed.

Access the downloadable, printable PDF version of this brochure below for easy offline reading or sharing. 

Biomarker Brochure PDF

Why are the two sides different?

Under a microscope, most colorectal cancers look alike. But tumors on each side tend to have different genetic changes driving their growth. Several factors likely play a role: 

  • The two halves of the colon develop from different tissues before birth. 
  • The chemicals in contact with the colon wall change as food is digested. 
  • The community of bacteria in each part of the colon (the microbiome) is different. 

When and how is sidedness determined?

Sidedness is determined at diagnosis. Your tumor’s location may be described in your imaging, surgical, or pathology reports. If you’re not sure where your tumor is, ask your care team. 

Unlike most biomarkers, sidedness doesn’t need a special test. But it’s only one part of the picture. Ask your care team about complete biomarker testing of your tumor, including RAS, BRAF, MSI/MMR, and HER2. 

How do right- and left-sided cancers differ? 

  Right-sided cancers  Left-sided cancers 
 Who it affects more   often  Women and older adults  Men and younger adults 
 How it’s found  Often flat and harder to see during colonoscopy, so more likely found at a later stage  Easier to see during colonoscopy and more often found at an earlier stage 
 Common symptoms  Anemia (low iron), fatigue, unexplained weight loss, or dark, tarry stools  Constipation, changes in bowel habits, narrow stools, bright red blood, or abdominal pain 
 Common   biomarkers  MSI-H/dMMR, KRAS or BRAF mutations; linked to Lynch syndrome  RAS/BRAF wild-type (about half of cases); HER2 amplification is more common here, though still uncommon (about 5% of colorectal cancers, somewhat higher in RAS wild-type tumors) 
 Where it tends to   spread  More likely to spread to the peritoneum (the lining of the abdomen)  More likely to spread to the liver or lungs 

Some of these differences come from the tumor’s other biomarkers, not just its location. For example, spread to the peritoneum is more common in dMMR tumors, which are more often right-sided. This is another reason your full biomarker results matter. 

What does sidedness mean for my outlook?

Every person’s cancer is different, and sidedness is just one of many factors that shape your outlook. Your stage, your biomarkers, how your cancer responds to treatment, and your overall health all play a role. 

Research shows some general patterns. At earlier stages (I and II), people with right-sided cancers do as well as, and sometimes better than, people with left-sided cancers. At later stages, left-sided cancers tend to have better results, partly because certain biomarkers, like BRAF mutations, are more common on the right side. 

The good news is that knowing your sidedness and biomarkers helps your care team match you with the treatments most likely to work for you, and treatment options continue to grow. Ask your care team what your results mean for you. 

What does sidedness mean for my treatment? 

Sidedness alone doesn’t determine your treatment. It works together with your other biomarker results, such as RAS, BRAF, MSI/MMR, and HER2, to guide your care. That’s why complete biomarker testing is so important. 

  • Stages I–III: Surgery and chemotherapy are the main treatments regardless of which side your tumor is on. 
  • Stage IV or recurrent cancer: This is where sidedness matters most. 
    • If your tumor is left-sided and RAS/BRAF wild-type, an EGFR inhibitor (cetuximab or panitumumab) may be added to FOLFOX or FOLFIRI chemotherapy. These drugs work best in left-sided cancers. 
    • Bevacizumab (Avastin) may be added to chemotherapy for tumors on either side. For right-sided tumors, it’s often the preferred choice. 
  • MSI-H/dMMR cancers: Immunotherapy with a checkpoint inhibitor is the most effective treatment, whichever side the tumor is on. Right-sided tumors are simply more likely to be MSI-H/dMMR. 
  • Other biomarkers can change the plan regardless of side. These include BRAF V600E, KRAS G12C, and HER2. Ask your oncologist what your results mean for you. 

Life after surgery 

Right-sided tumors: Surgery may remove the cecum, ascending colon, and part of the transverse colon. Looser, more frequent stools are common at first and usually improve over time as your body adjusts. Ask your care team whether an anti-diarrheal like Imodium®, a fiber supplement like Metamucil®, or diet changes might help. 

Left-sided tumors: Surgery may remove part of the transverse, descending, or sigmoid colon, and sometimes part of the rectum. Stools often become more formed after surgery, and many people return to a more normal bowel pattern over time. 

If your tumor was very low in the sigmoid colon or in the rectum, you may have a low anterior resection (LAR). Some people develop low anterior resection syndrome (LARS) afterward, which can cause urgency, frequent bowel movements, and other changes. Learn more on our LARS page. 

Questions to ask your care team 

  • Where in my colon or rectum did my tumor start, and does that make it right- or left-sided? 
  • Does my tumor’s location change my treatment now, or only if my cancer spreads or comes back? 
  • Has my tumor had complete biomarker testing, and what do my results mean for my treatment? 
  • What bowel changes should I expect after surgery, and how can I manage them? 
  • Should my family or I be tested for Lynch syndrome? 

Patient pro tips 

Treatments keep evolving, and not every doctor may bring up sidedness. Knowing where your cancer started can bring clarity and help you advocate for yourself.

“My cancer appeared on the right side. I have often wondered why the right side seems to be more common in the African American community. I am not tracking it, but when I talk with other survivors and compare cancers, the right side seems like it’s more common in my community, and my medical team said the same thing.” 

Cheryl Alston, stage II survivor 

“Knowing my tumor was on the left side of my body brought me clarity as I finally understood the ‘why and how.’ Although I have a high pain tolerance, this proved to me I wasn’t crazy: The pain was real and so severe, at times I felt spasmodic. The final results were very important to me as I was misdiagnosed on two previous occasions.” 

Kim Houston, stage III survivor 

“My tumor was rectal, about 3.5 cm above the anal verge. So, it’s left-sided. That said, I have had polyps in the ascending colon removed which were non-cancerous. I’d say I do have right-side risk for that reason. I’ve decided to dramatically limit alcohol consumption as a result, because that’s about my only risk factor. I’m negative for Lynch. I’m only having one bottle of wine per month now. One thing I’d mention about right vs. left side is that anecdotally, I’ve heard that right-side tumors have fewer obvious symptoms such as visible bleeding, so they can be more dangerous by being found later once cancer has spread. Screening is extremely important for avoiding right-side tumors, and young people especially need to be getting fecal testing done, check blood iron levels for anemia, and consider an early colonoscopy.” 

Chris Carvalho, stage II survivor

The best treatment is different for everyone. Talk with your care team about your options and whether additional biomarker testing could help.

Sources 

Sidedness Brochure Sources: 

Fight Colorectal Cancer. Sidedness biomarker. Fight Colorectal Cancer; 2026. https://fightcolorectalcancer.org/patient-caregivers/education-resources/diagnostic-tests-scans/biomarker-testing-checklist/sidedness-biomarker/  

Bensojn AB, Venook AP, Adam M, et al. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(2D):e240029. https://doi.org/10.6004/jnccn.2024.0029 

Benson AB, Venook AP, Adam M, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(6):366–375. https://doi.org/10.6004/jnccn.2024.0041 

NCCN Guidelines for Patients®: Colon Cancer. National Comprehensive Cancer Network; 2025. https://www.nccn.org/patientguidelines 

NCCN Guidelines for Patients®: Rectal Cancer. National Comprehensive Cancer Network; 2026. https://www.nccn.org/patientguidelines 

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. 

American Cancer Society. Colorectal Cancer Facts & Figures 2023–2025. American Cancer Society; 2023. https://www.cancer.org/research/cancer-facts-statistics/colorectal-cancer-facts-figures.html 

Weiss L, Stintzing S, Modest DP, et al. First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF-mutated metastatic colorectal cancer according to primary tumor sidedness: a pooled analysis of seven clinical trials (German AIO Study Group). Eur J Cancer. 2025;232:116105. https://doi.org/10.1016/j.ejca.2025.116105 

NCCN Guidelines for Patients®: Rectal Cancer. National Comprehensive Cancer Network; 2026. 

Yanova M, Maltseva D, Tonevitsky A. Sidedness matters: single-cell perspectives on left- and right-sided colorectal cancer. Front Cell Dev Biol. 2025;13:1720996. 

Moretto R, Rossini D, Conca V, et al. Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapies. NPJ Precis Oncol. 2025;9(1):118. 

Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017;84:69-80. 

Kander EM, Bhatt DL, Bhatt SB. Impact of colorectal cancer sidedness and location on therapy and clinical outcomes: role of blood-based biopsy for personalized treatment. Int J Mol Sci. 2023;24(13):11023. 

Maconi G, Manes G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol. 2008;14(8):1149-1155. 

Gámez-Chiachio M, et al. Iron deficiency anemia in colorectal cancer patients: is preoperative intravenous iron infusion indicated? A narrative review of the literature. J Clin Med. 2023;12(4):1508. 

Yoshino T, Watanabe J, Shitara K, et al. Panitumumab versus bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 2023;329(15):1271-1282. 

Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10-32. 

Messersmith WA, Khorana AA, Bhatt DL, et al. Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(2D):e240029. 

Watanabe J, Muro K, Shitara K, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer [PARADIGM]. JAMA. 2023;329(15):1271-1282. 

Kastrinos F, Syngal S. Hereditary nonpolyposis colon cancer (Lynch syndrome). In: StatPearls. StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK564511/ 

Cleveland Clinic. Lynch syndrome: signs/symptoms, causes, outlook. Cleveland Clinic; 2023. https://my.clevelandclinic.org/health/diseases/17195-lynch-syndrome-and-hnpcc 

André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207-2218. 

American Cancer Society. Questions to ask your doctor about colorectal cancer. American Cancer Society; 2024. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/talking-with-doctor.html